

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

SK-MEL-23

RRID:CVCL_6027

Type: Cell Line

Proper Citation

RRID:CVCL_6027

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6027

Proper Citation: RRID:CVCL_6027

Description: Cell line SK-MEL-23 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Cutaneous melanoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:978138](#), [PMID:1067619](#), [PMID:3518877](#), [PMID:6197381](#), [PMID:6582512](#), [PMID:6864164](#), [PMID:6933476](#), [PMID:7175440](#), [PMID:7509835](#), [PMID:7646526](#), [PMID:9670966](#), [PMID:9692547](#), [PMID:10766161](#), [PMID:15009714](#), [PMID:15467732](#), [PMID:17308088](#), [PMID:21725359](#), [PMID:22178978](#), [PMID:24576830](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#)

Comments: Characteristics: Very highly pigmented., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-MEL-23

Synonyms: SK-Mel-23, SK-Mel 23, SK-mel-23, SK MEL 23, SK Mel 23, Sk Mel23, SKMEL-23, SKMEL23, SKmel23, SK23-MEL, SK23-mel, SK23, AP-Mel

Cross References: BTO:BTO_0005333, EFO:EFO_0006490, BioSample:SAMN03470872, BioSample:SAMN03473194, cancercellines:CVCL_6027, CGH-DB:9318-4, Cosmic:706107, Cosmic:721823, Cosmic:851051, Cosmic:876705, Cosmic:888852, Cosmic:897493, Cosmic:905231, Cosmic:1060423, Cosmic:1303054, Cosmic:1507594, Cosmic:1669139, EGA:EGAS00001000610, EGA:EGAS00001002554,

GEO:GSM206542, GEO:GSM784516, Lonza:1343, PharmacDB:SK23_1416_2019, Progenetix:CVCL_6027, Wikidata:Q54953937

ID: CVCL_6027

Record Creation Time: 20220427T221545+0000

Record Last Update: 20260829T235928+0000

Ratings and Alerts

No rating or validation information has been found for SK-MEL-23.

No alerts have been found for SK-MEL-23.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kenski JCN, et al. (2023) An adverse tumor-protective effect of IDO1 inhibition. Cell reports. Medicine, 4(2), 100941.

Allard D, et al. (2023) The CD73 immune checkpoint promotes tumor cell metabolic fitness. eLife, 12.

Vredevoogd DW, et al. (2019) Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. Cell, 178(3), 585.